Goodnight,,,rant tomorrow and think on this.....
Thy will be done....
SLA QUESTIONS
The Solagran share register consists of many long term holders, both new and old, that believe in the long term objective of the company and have asked I send this to you.
Accordingly on behalf of the many smaller shareholders, I would request that any shareholder announcements are more definitive than subjective in nature to avoid any confusion as to the message which is intended. Adopting this approach would also better support the share price and reduce potential for manipulation.
If you could consider the aforementioned statement in your response to the following it would be beneficial in restoring management creditability and increasing shareholder awareness as to management’s approach. , the following is a listing of questions sought from Hotcopper, other similar internet sites and friends of mine whom have invested, some heavily, in Solagran.....
• What percentage of Ropen will be sold overseas, is it a case of having to supply Russia first and foremost, or the highest price wins?
• How many courses have been sold to date?
• Are overseas sales paid for immediately, by patients, to Solagran or invoiced to a medical institution. It helps for working out Quarterlies.
• Could sales numbers and of all SLA products, even if only invoiced, be noted in each quarterly, including which country received what numbers?
• How far progressed are the BIO-I trials among others?
• Who, and how many, are the Russian scientists and Administrators of Solalife, what are their roles, and how much of the 28mill shares go to each?
• Is Solalife the new Solamind with all/some of the holders, and is this issue of shares to compensate them for their losses in Opes Prime? If so then will Solamind be returning any monies back to Solagran they could back get from litigation.
• If any of the Solalife persons leaves or becomes unable to perform their full duties or is deceased, what happens to those shares, can we see the full contract before we vote?
• Will these shares be issued in accordance with the Remuneration Plan as of the 2007 AGM, E.G. Shares issued under this Plan are to be issued to Participants in July each year at Market Price.
• The issue of options to Denis and Vagif seem to be double dipping on the agreement from the last AGM, are they being issued above this agreement, or is it to compensate for losses as in Solamind’s case, if so will monies from litigation be returned to SLA? Perhaps the issue of Options should be valued in July next year, as SLA’s real value will be clearer then.
• Will SLA be announcing an independent director in the very near future? Many see this as paramount to a more open and better managed, Solagran.
• Have liver function tests qualitive/quantative data, ALT AST levels in particular, viral load PCR quantity IU/ml of blood detectable HCV virus in patients’ blood stream been done for Ropren as these results may determine efficacy of treatment, and apparently are recognised worldwide in clinical trials as leading indicators. If so will/when are these results to be announced?
• When will results be published in Medical Journals.
• Please explain the why Russia gets Ropren at a certain, cheaper price as compared to the rest of the world and how is this calculated?
• What is the cost of producing a course of Ropren, i.e. profit margins in this respect?
• Please explain the why Russia gets Ropren at a DISCOUNT price, as compared to the rest of the world, and how is this calculated? ; is it because Russia,, even though they sold ALL the rights to Bioeffectives,,( bar some fairness equation we all feel ), are providing Tomsk as an insensitive and SLA have done a ‘LONG TERM DEAL”?????, if so….what’s the deal?????......cheap for 20 years then market value?.....
• What is the cost of producing a course of Ropren, i.e. profit margins in this respect?
• What will, in your opinion, liposomal and nano technology do for the amount of Ropren necessary to achieve the same results as oral treatment?, and regardless of the format of delivery, will it be the same price per treatment?
• Do you think Vagif will meet the criteria for a Nobel Medical prize in 2012, in conjunction with the Aussie lads that found bacteria cause stomach ulcers, and make me happy?
Burp...I hope so.....
- Forums
- ASX - By Stock
- SLA
- quarterly out
quarterly out , page-22
-
- There are more pages in this discussion • 56 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SLA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
SBW
SHEKEL BRAINWEIGH LTD
Dani Nadri, Country Manager Australia
Dani Nadri
Country Manager Australia
SPONSORED BY The Market Online